Image default

How Did ElevateBio Manage To Nab $401M In This Economy?

ElevateBio, a Massachusetts-based gene therapy startup, announced on Wednesday it raised $401 million in Series D funding.

The company’s round was led by the AyurMaya Capital Management Fund, a VC fund managed by Matrix Capital Management, which joined Novo Nordisk, SoftBank Vision Fund 2 and Samsara BioCapital as part of ElevateBio’s investor syndicate.

Search less. Close more.

Grow your revenue with all-in-one prospecting solutions powered by the leader in private-company data.

“We have made significant strides in scaling our technologies and end-to-end capabilities in our pursuit to become the world’s most indispensable cell and gene therapy technology company,” ElevateBio CEO David Hallal said in a statement.

A fast-growing biotech startup

Boy, did they. ElevateBio, in my opinion, is pretty close to being its own big pharma company. The startup operates a slew of technology platforms that span from drug development to manufacturing and interconnect with one another, allowing ElevateBio to bring a drug from conceptualization all the way to commercialization. It even has a subsidiary, Life Edit, which develops therapeutics for genetic diseases.

But, since it isn’t, the startup has also inked a deal with an actual big pharma company: Novo Nordisk. Life Edit will work with Novo Nordisk to develop a suite of base editing therapies, which is a fancy way of saying they’re making drugs that can make changes to the DNA sequence.

Demand for cell and gene therapies is growing in part due to the promise that by adding genes to the body, or by correcting a defect in a gene, the immune system can fight its way through disease. The concept is pretty novel in that it may allow certain patients to circumvent managing disease on a daily basis.

ElevateBio is in a pretty unique position compared to its peers. Many startups are struggling under the funding environment imposed by close-fisted investors, and have had to slash research and development programs in order to conserve cash and extend their runway.

ElevateBio, in the meantime, has its hand in multiple drug development pipelines. The company also has a partnership with Moderna that was announced in February to develop in vivo mRNA gene editing therapeutics.

It seems like a big week for biotech — the second-largest fundraising round in the space happened yesterday when ReNAgade Therapeutics raised $300 million in Series A funding.

Stay up to date with recent funding rounds, acquisitions, and more with the
Crunchbase Daily.

Source link

Related posts

AI Was Q2’s Big Hope To Reverse The Global Venture Funding Slowdown. It Wasn’t Enough

Sarah Villa

Bold Commerce swaps CEOs, bringing on PayPal, Intuit alum Peter Karpas

Sarah Villa

Federal government reveals breakdown of $700 million renewed commitment to Innovation Clusters

Sarah Villa

PitchBook’s new tool uses AI to predict which startups will successfully exit

Sarah Villa

AI beauty lab Omy raises $11 million CAD to expand personalized skin care product line in North America

Sarah Villa

EV Asset And Lending Platform Finayo Raises Fresh Funding

Sarah Villa

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More